MAPT and supranuclear palsy, progressive, 1: Conflicting results have also been obtained in differentiating PSP patients from controls by dosing total or tangle-forming 181Thr-phosphorylated tau (p-tau181) [4] in CSF or plasma [21,22,23,24,25,26,27,28,29].